Skip to main content

Table 2 Baseline characteristics of the strategic treatment group and mismatched treatment group

From: Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study

Variables Strategic treatment (n=17) Mismatched (n=17) p value
Age (years) 53.2±16.0 58.4±10.8 0.5016
Male, n (%) 12 (70.5) 6 (35.3) 0.0084
Disease duration (months)
PSO 108 (42, 288) 216 (10, 258) 0.9176
PsA 42 (13.5, 116.5) 43 (16.5, 144) 0.7960
Peripheral arthritis 17 (100) 17(100) 1.0000
Spinal involvement 4 (23.5) 6 (35.2) 0.7080
History of past bDMARDs 1st 12 (70.5) 1st 12 (70.5) 1.0000
Concomitant MTX use 12 (70.6) 10 (58.8) 0.7270
bDMARDS initiated
IL-17-i/TNF-i 6 (35.2)/11 (64.7) 8 (47.0)/9 (52.9) 0.4905
Disease activity
TJC 7 (5, 8.5) 8 (3.5, 14) 0.4164
SJC 6 (4, 12.5) 5 (2.5, 7) 0.1453
CRP (mg/dl) 0.99 (0.18, 2.14) 0.54 (0.075, 1.71) 0.2347
DAPSA 24.1 (19.2, 33.7) 31.2 (20.9, 39.8) 0.1848
PASI 3.1 (0.5, 5.75) 1.6 (0.4, 6.3) 0.7823
  1. Data are expressed as mean ± standard deviation, median (interquartile range [IQR]), or number (%)
  2. TNF-i TNF inhibitors, IL-17-i IL-17 inhibitors, TJC tender joint counts 68, SJC swollen joint counts 66, DAPSA Disease Activity in Psoriatic Arthritis, PASI Psoriasis Area and Severity Index
  3. *p<0.05, by Mann-Whitney U test or chi-square test